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Any discussion of morbid events in diabetes is 
going to emphasize cardiovascular and peripheral 
vascular problems. Renal disease accounts for a rela-
tively small percentage of the mortality in diabetes; 
yet the overall incidence of diabetes mellitus in the 
population so greatly exceeds that of the various 
types of glomerulonephritis that it has become one of 
the most common causes of end-stage renal failure in 
this country. It is difficult to assign exact numbers 
because the figures in the medical literature vary con-
siderably; however, it is estimated that in the United 
States today there are some 10 million people who are 
known to be diabetic, who would be found to be 
diabetic if tested, or who during the course of their 
lives will develop overt diabetes. In autopsy series of 
diabetics the prevalence of glomerulosclerosis has 
varied from 15% to 82%, with a mean of approxi-
mately 30%. This figure will vary depending on how 
carefully the kidneys are studied, particularly with 
respect to the use of special stains for identifying 
glomerulosclerosis; the incidence will also increase 
with the proportion ofjuvenile to adult onset diabet-
ics included in the sample. Renal failure is listed as 
the cause of death of 6% to 12% of diabetics, and its 
incidence is increased seventeenfold in the diabetic 
population as compared to the nondiabetic. These 
figures are probably applicable to those diabetics who 
have many complications and who require referral to 
major medical centers for treatment. In terms of the 
general diabetic population renal failure is probably 
in the range of 1 % to 2%. This means that the preva-
lence of glomerulosclerosis is severalfold higher than 
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the prevalence of renal failure, and that simply find-
ing the lesion on biopsy does not indicate that kidney 
function itself has been impaired or that there will be 
any abnormalities present on urinalysis. As a cause of 
end-stage renal failure, diabetes now accounts for 
some 15% to 25% of all new cases. 
Five years' survival after onset of proteinuria in 
diabetics compared to age-matched controls is 65% 
opposed to 73% for diabetics who do not develop 
proteinuria and 83% for non-diabetics. This does not 
mean that these people are dying of renal disease but 
that proteinuria heralds increased mortality from all 
causes. For juvenile diabetics it is extremely unusual 
for proteinuria to develop before 10 years' duration 
of the disease or to appear after a protein-free inter-
val greater than 30 years. This means that there are 
essentially two populations of juvenile diabetics with 
regard to the kidney; those who will have their dis-
ease for an unlimited amount of time and never de-
velop renal complications, and those who during the 
period between IO and 30 years will note the onset of 
renal problems. Finally, in juvenile diabetes mellitus, 
azotemia defined as BUN in excess of 30 mg percent 
implies end-stage renal failure within three years. An 
important point to note is the rarity of a decline in the 
glomerular filtration rate before the onset of protein-
uria when the cause is diabetic nephropathy. Once 
renal failure does ensue it has been calculated that the 
glomerular filtration rate falls at an average rate of 1 
ml/min each month. With other forms of renal dis-
ease, hypertension greatly accelerates the rate of de-
cline in the glomerular filtration rate, an important 
point in treatment. 
Diabetic nephropathy and microangiopathy are 
the main topics under discussion here, but there are 
. several other factors which contribute in varying de-
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gree to the progression of renal failure in diabetics. 
As there is no therapy for diabetic nephropathy itself, 
these other factors assume an importance in line with 
their response to treatment. Infection, in particular 
pyelonephritis and papillary necrosis, becomes an ex-
tremely important factor in the management of the 
diabetic. This is true because the autonomic neuropa-
thy that may complicate diabetes favors development 
of a neurogenic bladder with high residual urine 
which may lead to reflux up the ureter, if the urine is 
infected, this reflux will result in secondary pyelone-
phritis and subsequent papillary necrosis with rapid 
loss of renal function. In patients who already have 
some type of renal failure, infection, even without 
involvement of the renal parenchyma, can result in a 
further decline in renal function. One of the theories 
that has been advocated to explain this is that certain 
types of bacteria can attach themselves to the cells of 
the ureter and thereby compromise the peristaltic 
action of the ureter which is important in propelling 
urine from the renal pelvis into the bladder. This 
results in a type of functional obstruction which acts 
in the same way as a true obstruction. Treatment of 
these patients with antibiotics to eradicate the bacte-
riuria improves ureteral peristalsis and renal function 
as well. 
Diabetes is also frequently complicated by hy-
perlipidemia and hyperuricemia. Uric acid crystals 
are a cause of interstitial nephritis, and high uric acid 
levels which lead to increased uric acid excretion can 
set the stage for uric acid calculi, obstruction, and 
subsequent infection. In the evaluation of a diabetic 
patient, the potential adverse effect of uric acid 
should be considered as this cause of renal failure is 
subject to therapy either by alkalinization of the urine 
or the use of allopurinol. 
A number of cardiovascular problems will also 
contribute to the declining glomerular filtration rate. 
Hypertension has already been mentioned; this can 
accelerate the vascular degenerative changes in the 
kidney, leading to nephrosclerosis which in turn can 
accelerate the hypertension, creating a cycle which 
may be interrupted if the hypertension is successfully 
controlled through the careful use of antihypertensive 
medication. Another complication of hypertension is 
its deleterious effect on the myocardium, leading to 
hypertensive cardiomyopathy and congestive heart 
failure. This will have an adverse effect on renal func-
tion, for as the kidney is damaged secondary to dia-
betes or other processes and as the vascular disease in 
the kidney progresses, autoregulation of blood flow 
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in the face of a reduced cardiac output is com-
promised; thw; low-output congestive heart failure 
will result in prerenal azotemia superimposed on the 
preexisting ren.il failure. In general, this situation is 
handled by the combination of digitalization and di-
uretics; however, it is worth pointing out the prob-
lems associated with excessive use of diuretics in these 
patients. They may get too dehydrated, a factor that 
will superimpose a prerenal type of azotemia upon 
their already preexisting level of renal failure. A com-
promise has to be worked out in terms of controlling 
the symptoms of congestive heart failure without, at 
the same time, contributing further to the impairment 
of renal function. Diabetics are prone to develop 
atherosclerosis, and particularly those patients who 
have extremely severe atheromatous disease of the 
aorta are subject to embolization to the renal vessels. 
This can present as episodic elevations of blood pres-
sure associated with fluctuations in the level of renal 
function reflected by BUN and creatinine and accom-
panied by microscopic or even gross hematuria, de-
pending on how much of the kidney is damaged or 
destroyed by infarction. 
The actual role of platelets in renal disease is still 
largely uncertain, although there is strong circum-
stantial evidence that platelets may be an important 
factor in the decline in renal function not only in 
diabetes but in glomerulonephritis as well. However, 
the abnormal properties of platelets in diabetes in-
crease the level of suspicion that they have a major 
role in the pathogenesis of the renal disease.' In the 
laboratory, platelets are studied by incubating them 
with various agents such as adenosine diphosphate, 
epinephrine, and collagen, which induce aggregation. 
The Table shows that the percent aggregation of 
platelets in diabetics to all three aggregating agents 
exceeds the control sample; moreover, platelets from 
diabetics aggregate at a lower concentration of these 
agents than the control sample. The reason for this is 
not exactly clear, but there is current evidence for a 
disturbance of prostaglandin synthesis by the plate-
lets of diabetics. The Figure shows the synthesis of 
immunoreactive prostaglandin E following the addi-
tion of a precursor of prostaglandin synthesis, arachi-
donic acid. Diabetic platelets show enhancement of 
prostaglandin formation following addition of the 
precursor. Thus with the evidence that platelets are 
more sticky in the diabetic and aggregate more easily, 
the possibility has been raised that within the micro-
circulation of the kidney, platelet aggregation occurs 
and leads to occlusion of the small blood vessels, 
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TABLE 
Percent Aggregation Four Minutes After the Addition of Each of 
the Aggregating Agents 
AGGREGATION(%) 
AGGREGATING DIABETIC 
AGENT CONTROLS SUBJECTS P VALUE* 
ADP: 
lµM 22 ± 7t 80 ± 4 (9):j: <0.001 
2µM 69 ± 4 88 ± 4(9) <0.005 
5µM 76 ± 4 
Epinephrine: 
86 ± 3 (9) NS§ 
lµM 39 ± 8 82 ± 5 (IO) <0.001 
2µM 60 ± 6 85 ± 3(9) <0.01 
5µM 66 ± 6 84 ± 2(10) <0.005 
Collagen: 
I µg/ ml 53 ± 10 80 ± 3 (8) < 0.05 
2µg/ml 69 ± 8 84 ± 4 (8) NS 
IOµg/ ml 77 ± 8 86±3(8) <0.05 
* Difference between % aggregation seen in the platelet-rich 
plasma obtained from control and that in diabetic subjects. 
t Mean± SEM. 
:j: Figures in parentheses denote no. of subjects 
§ Not significant. 
resulting in glomerular ischemia and glomeruloscle-
rosis. There is some further evidence that involves 
platelets: thromboglobulin, a protein which is derived 
from the platelet, has been found to be increased in 
the circulation of those diabetics who have micro-
angiopathy. There are also tests for the presence of 
circulating platelet aggregates, and those diabetics 
who have the most severe small vessel disease are also 
the ones who show the highest levels of these circulat-
ing platelet aggregates. A recent study2 reported on 
the efficacy of sulfinpyrazone in the prevention of 
morbid events in patients who have severe coronary 
artery disease. There are active studies in progress to 
evaluate antiplatelet drugs in a variety of diseases 
that affect blood vessels, particularly coronary artery 
disease, atherosclerosis, and different types of renal 
disease. 
Amyloidosis is always listed as associated with 
diabetes mellitus. Certainly the onset of nephrotic 
syndrome or heavy proteinuria in a patient with long-
standing diabetes does raise the possibility that sec-
ondary amyloidosis may be present. With respect to 
immunologic factors which crop up in consideration 
of almost every type of renal disease, immuno-
globulins and complements are found within the 
glomerulus of the diabetic kidney. Their presence in a 
rather nonspecific pattern together with several other 
serum proteins has been interpreted not to represent 
a specific immunologic event such as immune com-
plex disease or anti-glomerular basement membrane 
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(anti-GBM) disease. Still, there are some lines of 
evidence which do not exclude completely the idea 
that immunologic problems are present in the dia-
betic and may be contributing to the renal disease. It 
was recently reported that juvenile _diabetes mellitus 
can be viewed as a genetic disease transmitted as an 
autosomal recessive gene.3 More interesting, perhaps, 
is the close association of the diabetic gene with the 
HL-A locus. This area of the chromosome is con-
cerned with a variety of immunologic responses, and 
many other diseases which have a close association 
with the HL-A locus have been more firmly estab-
lished as being the result of an immunologic abnor-
mality. Based on this there is still speculation that the 
diabetic may have altered immunologic responses 
and that this in turn may lead to primary or second-
ary renal damage. 
Drug-induced disease of the kidney, while not con-
fined to the diabetic, may assume increased signficance 
for these patients. There have been several reports of 
acute renal failure following the use of iodine con-
trast agents; for the most part, this can be prevented 
in the nondiabetic population by avoiding dehy-
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MINUTES AFTER ADDITION OF ARACHIDONIC ACID 
Figure-Time course for the production of iPG E in platelet-rich 
plasma (PRP) from exogenous arachidonic acid (0.5mM). The 
values are the mean ± SEM for nine subject pairs. 
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dration which is part of the preparation of patients 
for radiologic examinations. Diabetics, however, 
tend to develop acute renal failure with a greater 
frequency than nondiabetics; moreover, avoiding de-
hydration does not seem to be protective. This sug-
gests that something about the diabetic kidney pre-
disposes it to damage in the face of a quantity of 
hyperosomotic material. The question arises whether 
the diabetic kidney is more susceptible to other neph-
rotoxic agents such as the aminoglycoside antibiotics 
and a host of other medications which have potential 
nephrotoxicity. The lack of a definite answer suggests 
that in the management of diabetics both diagnostic 
and therapeutic agents should be selected for their 
reduced incidence of nephrotoxicity. 
Several studies have attempted to identify fac-
tors of importance in determining the development 
and progression of diabetic nephropathy. The data to 
be presented were derived from a small number of 
patients with biopsy-proven glomerulosclerosis who 
were followed for several years at which time a repeat 
biopsy was performed.' As far as the type of diabetes 
is concerned, of the 11 adult onset diabetics, 9 
showed no progression of their glomerulosclerosis, 
and 2 became worse. In contrast, of the 6 juvenile 
diabetics, l showed no change and 5 showed progres-
sion of the disease. With regard to blood glucose 
control, 6 of the patients maintained good sugar con-
trol for the whole length of the study and none of the 
6 showed progression of their glomerulosclerosis. By 
contrast, 13 patients were rated to be poorly con-
trolled and IO of them showed a progression of their 
renal lesions. In respect to the age of onset of these 
diabetics, patients in the group that showed no 
change were considerably older at the time of the 
onset of their diabetes than were those in the group 
that became worse. Obviously these three variables 
are not independent since, by and large, in older 
patients the adult onset type of diabetes can easily be 
managed by diet and weight reduction. But the re-
sults do suggest that blood glucose control may be 
important in terms of slowing down or averting the 
development of glomerulosclerosis. 
There appear then to be at least three phases in 
the renal disease that accompanies diabetes . The first 
is a pre-proteinuria phase. Phase 2 is marked by the 
onset of proteinuria, and phase 3 would be develop-
ment of azotemia. Several groups have tried to study 
the question, Is there anything abnormal about the 
kidney in the pre-proteinuric phase?, that is, before 
proteinuria becomes manifest and at a time when the 
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other renal function tests are also normal.6 If glo-
merulosclerosis progresses slowly with time, there 
might be a gradual increase in the excretion of albu-
min in the urine as the function of the duration of the 
diabetic process until such time as the amount of 
albumin in the urine definitely reaches an abnormal 
quantity. In a study of 97 young male diabetics who 
were followed from 1-19 or more years after the 
diagnosis of diabetes, there was no increase in albu-
min excretion throughout this period of time. Those 
who develop proteinuria are clearly distinguished 
from those who do not. Because strenuous exercise 
increases albumin excretion, a group of 13 juvenile 
diabetics were exercised at a rate which had not af-
fected urinary albumin levels in 9 normal controls. 
The diabetics showed a statistically significant in-
crease in protein excretion that returned to baseline 
after stopping the exercise. Another element that has 
been examined is the excretion of low molecular 
weight proteins by diabetics; these represent proteins 
that are considerably smaller than albumin and are 
freely filtered at the glomerulus. Almost none, how-
ever, appear in the urine because most of these fil-
tered proteins are reabsorbed by the cells of the prox-
imal tubule . In the pre-proteinuric phase, diabetics 
show an increase in excretion of low molecular 
weight proteins. These results, together with addi-
tional information on albumin excretion, suggest that 
the metabolic state of diabetes can adversely affect 
renal cell function so that when the diabetic is poorly 
controlled, the cells are less able to reabsorb filtered 
proteins, including albumin. 
In addition to studies on patients, there have 
been attempts to gain information about diabetes 
through the use of animal models. Diabetes may be 
induced in animals either by removing the pancreas 
or by destroying the insulin-producing cells with a 
chemical such as streptozotocin. These animals then 
develop hyperglycemia and over the next several 
months their kidneys will show the kind of lesions 
that are present in humans: namely, there is an in-
crease in the mesangial matrix and an increase in the 
degree of glomerulosclerosis together with deposition 
of immunoglobulins and complement. If the kidneys 
from a diabetic animal are transplanted into a normal 
animal, the diabetic changes rapidly disappear. On 
the other hand, if kidneys from a normal animal are 
transplanted into a diabetic animal, diabetic changes 
will develop. When pancreatic tissue is successfully 
transplanted into the diabetic animal, then coincident 
with the rise in insulin level, there is striking improve-
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ment in the appearance of the diabetic kidney. This 
indicates that the changes seen in the glomerulus are 
at least initially reversible and that metabolic control 
of blood glucose, or at least the presence of insulin in 
appropriate quantities to keep the blood glucose nor-
mal, is a contributing factor to the development of 
diabetic changes. 
The outline for therapy of diabetic kidney dis-
ease calls for the best blood glucose control circum-
stances will permit. Antihypertensive therapy has to 
be emphasized together with optimal management of 
congestive cardiac failure in order to maintain a high 
cardiac output and avoid prerenal azotemia. The pa-
tient should be evaluated for obstruction and for 
urinary tract infection. Nephrotoxic agents should be 
avoided as much as possible. As for vascular compli-
cations, anticoagulation offers little value as, by and 
large, patients who have renal disease also have reti-
nal disease which is aggravated by these drugs. The 
antiplatelet drugs, based on available evidence, are 
quite promising, although unproven at the present 
time. As far as the treatment of end-stage renal dis-
ease in the diabetic is concerned, the same four mo-
dalities are open to these patients as anyone else: 
living related transplants, cadaver transplants, hemo-
dialysis and peritoneal dialysis . Because of technical 
advances, greater experience in dealing with diabet-
ics, and earlier acceptance of diabetics into end-stage 
renal failure programs, the prognosis has improved 
considerably during the past couple of years.6 Trans-
plantation from a living related donor seems to be as 
good in diabetics as in the general population, so that 
this would seem to be the treatment of choice for a 
diabetic with end-stage renal disease. The results with 
cadaver kidney transplantation tend to be poorer 
than those of the general population and until we 
have some better methods of managing cadaver kid-
ney transplants in general, this is probably the least 
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promising mode of therapy for the diabetic. Hemo-
dialysis is the treatment that will be applied to the 
majority of these people. The problems are in estab-
lishing a suitable blood access site because of severe 
vascular disease and the requirement for anti-
coagulation during dialysis which frequently leads to 
a deterioration of vision. Many nephrologists now 
feel that the treatment of choice if a living related 
donor is not available is peritoneal dialysis; the major 
problem here is peritonitis as well as the necessity for 
using high-glucose containing solutions in the perito-
neal cavity which can lead to severe degrees of hyper-
glycemia, but the complications associated with 
bleeding in the eye are avoided and vascular access is 
not necessary. 
The table and the figure are reproduced with permission from 
the New England Journal of Medicine (297:1306-1310, 1977). 
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